|
Leukemia, Myelocytic, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although the majority of congenital neutropenia patients respond to daily granulocyte colony stimulating factor, approximately 15 % do not respond to this cytokine at doses up to 50 μg/kg/day and approximately 15 % of patients will develop myelodysplasia or acute myeloid leukemia.
|
31248972 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delay due to neutropenia was higher in patients who received granulocyte-colony stimulating factor on day 1.
|
31042138 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated a retrospective cohort of 228 adult lung transplant recipients between 2008 and 2013 to assess the association of neutropenia and granulocyte colony-stimulating factor (GCSF) treatment with outcomes.
|
31452317 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
He responded well to filgrastim (Neupogen) and blood transfusions, so a drug-related cause of neutropenia has been suspected.
|
31142911 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delays due to neutropenia and leukopenia were significantly decreased among patients that received G-CSF (OR 0.098, 95% CI 0.06-0.15 and OR 0.32, 95% CI 0.18-0.58, respectively).<b>Discussion:</b> In conclusion, G-CSF support reduces neutropenic events and permits increased relative dose intensity, which is essential for improved survival outcomes.
|
31583943 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of granulocyte colony-stimulating factor can be beneficial to shorten the duration of neutropenia.
|
31842164 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is widely used for prophylaxis and treatment of neutropenia in cancer patients and also for peripheral blood stem cells (PBSC) mobilization.
|
31003920 |
2020 |
|
Lymphoma, Non-Hodgkin
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to estimate, from a US payer perspective, the incremental costs of FN hospitalizations and the total incremental costs associated with PEG-OBI prophylaxis at varying device failure rates over assured FN prophylaxis with daily injections of filgrastim or filgrastim-sndz or a single injection of pegfilgrastim.<b>Methods:</b> Cost simulations comparing prophylaxis with PEG-OBI at failure rates of 1-10% versus assured prophylaxis in cycle 1 of chemotherapy were performed for panels of 10,000 patients with lung cancer treated with cyclophosphamide, doxorubicin, and etoposide (1 analysis) or non-Hodgkin lymphoma (NHL) treated with CHOP or CNOP (2 analyses).
|
31433700 |
2020 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM).
|
31534192 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delay due to neutropenia was higher in patients who received granulocyte-colony stimulating factor on day 1.
|
31042138 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated a retrospective cohort of 228 adult lung transplant recipients between 2008 and 2013 to assess the association of neutropenia and granulocyte colony-stimulating factor (GCSF) treatment with outcomes.
|
31452317 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
He responded well to filgrastim (Neupogen) and blood transfusions, so a drug-related cause of neutropenia has been suspected.
|
31142911 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of granulocyte colony-stimulating factor can be beneficial to shorten the duration of neutropenia.
|
31842164 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delays due to neutropenia and leukopenia were significantly decreased among patients that received G-CSF (OR 0.098, 95% CI 0.06-0.15 and OR 0.32, 95% CI 0.18-0.58, respectively).<b>Discussion:</b> In conclusion, G-CSF support reduces neutropenic events and permits increased relative dose intensity, which is essential for improved survival outcomes.
|
31583943 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is widely used for prophylaxis and treatment of neutropenia in cancer patients and also for peripheral blood stem cells (PBSC) mobilization.
|
31003920 |
2020 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further studies on the roles of CCL11, CXCL10, and G-CSF may be especially important in terms of potential prevention of SAE between 4 and 24 h after the onset of sepsis.
|
31628962 |
2020 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neutrophils from older adults appear to be dysfunctional, displaying a reduced ability to target infected or inflamed tissue, poor phagocytic responses and a reduced capacity to release neutrophil extracellular traps (NETs); this occurs in health, but responses are further diminished during infection and particularly during sepsis, where a reduced response to granulocyte colony-stimulating factor (G-CSF) inhibits the release of immature neutrophils from the bone marrow.
|
31732687 |
2020 |
|
Sepsis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neutrophils from older adults appear to be dysfunctional, displaying a reduced ability to target infected or inflamed tissue, poor phagocytic responses and a reduced capacity to release neutrophil extracellular traps (NETs); this occurs in health, but responses are further diminished during infection and particularly during sepsis, where a reduced response to granulocyte colony-stimulating factor (G-CSF) inhibits the release of immature neutrophils from the bone marrow.
|
31732687 |
2020 |
|
Sepsis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further studies on the roles of CCL11, CXCL10, and G-CSF may be especially important in terms of potential prevention of SAE between 4 and 24 h after the onset of sepsis.
|
31628962 |
2020 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
For biosimilar filgrastim, phase III confirmatory clinical studies were performed in the most sensitive population, patients with breast cancer undergoing myelosuppressive chemotherapy.
|
31440986 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sandoz biosimilar filgrastim was approved based on Phase III confirmatory studies conducted in patients with breast cancer experiencing chemotherapy-induced neutropenia, with other indications granted based on extrapolation.
|
31405784 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we summarise previously reported and report two new independent cases of G-CSF-induced aortitis, both in patients treated with chemotherapy for breast cancer.
|
30959218 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In phase III trials, once per cycle prophylaxis with mecapegfilgrastim was more effective than placebo in reducing the incidence of grade ≥ 3 neutropenia in cycle 1 in patients with advanced non-small cell lung cancer and was more effective than filgrastim at reducing the mean duration of grade ≥ 3 neutropenia in cycle 1 in patients with breast cancer.
|
31489570 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
With regard to immune dysfunction, we observed that the motility-increased C3 subtype exhibited high granulocyte colony stimulating factor (G-CSF) expression accompanied by neutrophil aggregation.
|
30778902 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
|
31728715 |
2019 |